About
GlaxoSmithKline (GSK) is advancing quantum computing applications in pharmaceutical research. It partners with IBM, using the Quantum Heron and Condor processors for mRNA codon optimization and clinical data analysis, and works with D-Wave on quantum annealing for genetic algorithms. The company collaborated with Capgemini UK and the National Quantum Computing Centre on quantum-enhanced drug discovery, developing machine learning pipelines that use quantum features to predict the reactivity of targeted covalent drugs. Led by Ross Walker, Global Director of Scientific Research Computing & Analytics, GSK takes part in the QuPharm consortium alongside other major pharmaceutical companies to structure quantum computing's potential in drug discovery, focusing on optimization problems that exceed traditional computational capabilities in messenger RNA research and therapeutic development.
Quantum Specifications
| Quantum Focus | software |